Single Source: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center

The National Institute of Mental Health (NIMH) intends to publish a single source Notice of Funding Opportunity (NOFO) to renew support of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center, to continue core program activities, such as management, direction, and coordination, including data processing and analysis to support the AMP SCZ Clinical Trial Network awarded under RFA-MH-24-150. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop a responsive application. This NOFO will utilize the U24 activity code. Investigators from Brigham and Women's Hospital awarded under RFA-MH-24-151 with expertise and insights in coordinating a wide scope of activities, including working with clinical research organizations, to support the use of pharmacological interventions for psychosis are encouraged to consider applying for this NOFO. In addition, collaborative investigations combining expertise in bioinformatics and data processing appropriate to establish and implement the procedures for collecting, processing, and analyzing specialized biomarker and digital data types, including multi-modal data analysis should also consider collaborating for this application.